// App-Quantinova.ai

1754 : Caplacizumab Induces Fast and Durable Platelet Count Responses with Improved Time to Complete Remission and Recurrence-Free Survival in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Researchers

Presenter

  • Paul Coppo

Principal Investigators

  • Marie Scully

  • Javier de la Rubia

  • Flora Peyvandi

  • Spero Cataland

  • Johanna A Kremer Hovinga Strebel

  • Paul Knoebl

  • Katerina Pavenski

  • Jessica Minkue Mi Edou

  • Filip Callewaert

  • Rui de Passos Sousa

Medical Centers

  • Department of Hematology, Reference Center for Thrombotic Microangiopathies (CNR-MAT), Saint-Antoine University Hospital, AP-HP, Paris, France

  • Cardiometabolic Programme, NIHR UCLH/UCL BRC, Department of Haematology, University College London Hospital, London, United Kingdom

  • Hematology Department, Internal Medicine, School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain

  • Hospital Dr Peset, Valencia, Spain

  • Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Milan, Italy

  • Department of Pathophysiology and Transplantation, Universit degli Studi di Milano, Milan, Italy

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Hematology and Central Hematology Laboratory, Inselspital, University Hospital of Bern, Bern, Switzerland

  • Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

  • Departments of Laboratory Medicine and Pathobiology, Medicine, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada

  • Sanofi, Zwijnaarde, Belgium

  • Sanofi, Diegem, Belgium

  • Sanofi, Lisbon, Portugal

Locations

  • France

  • United Kingdom

  • Spain

  • Italy

  • United States

  • Switzerland

  • Austria

  • Canada

  • Belgium

  • Portugal

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Thrombotic thrombocytopenic purpura

  • Tuberculosis

Biomarkers

  • N/A

Drug/Treatment

  • ALX-0081

Outcome

  • N/A

Study Design

  • Placebo Control

  • Open Label

Phase

  • III

Study Id's

  • NCT02553317

Sponsors

  • Ablynx

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved